المؤلفون: Solh, M, Bahlis, NJ, Raje, NS, Costello, CL, Dholaria, B, Levy, MY, Tomasson, MH, Dube, H, Damore, MA, Lon, HK, Basu, C, Skoura, A, Chan, EM, Trudel, S, Jakubowiak, A, Chu, MP, Gasparetto, C, Dalovisio, A, Sebag, M, Lesokhin, AM

المصدر: In Hematology, Transfusion and Cell Therapy October 2021 43 Supplement 1:S195-S196

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Wang HY; Division of Laboratory and Genomic Medicine, Department of Pathology, University of California San Diego Health Sciences, La Jolla, California, USA., Louis HMS; Division of Laboratory and Genomic Medicine, Department of Pathology, University of California San Diego Health Sciences, La Jolla, California, USA., Costello CL; Division of Blood and Marrow Transplant, Department of Medicine, University of California San Diego Health Sciences, La Jolla, California, USA., Murray SS; Division of Laboratory and Genomic Medicine, Department of Pathology, University of California San Diego Health Sciences, La Jolla, California, USA., Dell'Aquila ML; Division of Laboratory and Genomic Medicine, Department of Pathology, University of California San Diego Health Sciences, La Jolla, California, USA.

المصدر: British journal of haematology [Br J Haematol] 2024 Jul; Vol. 205 (1), pp. 364-367. Date of Electronic Publication: 2024 May 12.

نوع المنشور: Case Reports; Review; Letter; Journal Article

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Histone-Lysine N-Methyltransferase*/genetics , Myeloid-Lymphoid Leukemia Protein*/genetics, Humans ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/diagnosis ; Gene Amplification ; Male ; Gene Rearrangement ; Adult ; Female

المؤلفون: Rifkin RM; Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO 80218, USA., Costello CL; Department of Medicine, Division of Blood & Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA., Birhiray RE; Hematology Oncology of Indiana/American Oncology Network, Indianapolis, IN 46260, USA., Kambhampati S; Kansas City Veterans Affairs Medical Center, Kansas City, MO 64128, USA., Richter J; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Abonour R; Indiana University School of Medicine, Indianapolis, IN 46202, USA., Lee HC; M.D. Anderson Cancer Center, Houston, TX 77030, USA., Stokes M; Evidera, Data Analytics, St-Laurent, Quebec, H4T 1V6, Canada., Ren K; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02412, USA., Stull DM; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA., Cherepanov D; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA 02412, USA., Bogard K; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA., Noga SJ; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA 02421, USA., Girnius S; TriHealth Cancer Institute, Cincinnati, OH 45247, USA.

المصدر: Future oncology (London, England) [Future Oncol] 2024 Jan; Vol. 20 (3), pp. 131-143. Date of Electronic Publication: 2023 Oct 09.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/diagnosis , Multiple Myeloma*/drug therapy, Humans ; Bortezomib/adverse effects ; Lenalidomide/therapeutic use ; Dexamethasone ; Glycine ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Boron Compounds/adverse effects

المؤلفون: Bahlis NJ; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada. nbahlis@ucalgary.ca., Costello CL; Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA., Raje NS; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA., Levy MY; Department of Medical Oncology, Baylor Scott and White Health, Dallas, TX, USA., Dholaria B; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Solh M; Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA, USA., Tomasson MH; Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA., Damore MA; Oncology Research and Development, Pfizer Inc., San Diego, CA, USA., Jiang S; Early Clinical Development, Pfizer Inc., San Diego, CA, USA., Basu C; Early Clinical Development, Pfizer Inc., San Diego, CA, USA., Skoura A; Early Clinical Development, Pfizer Inc., Collegeville, PA, USA., Chan EM; Oncology Research and Development, Pfizer Inc., South San Francisco, CA, USA., Trudel S; Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Jakubowiak A; Department of Medicine, University of Chicago Medical Center, Chicago, IL, USA., Gasparetto C; Department of Medicine, Duke University Cancer Institute, Durham, NC, USA., Chu MP; Cross Cancer Institute, Edmonton, AB, Canada., Dalovisio A; Department of Hematology and Oncology, Ochsner Health, New Orleans, LA, USA., Sebag M; Cedars Cancer Center, McGill University Health Center, Montreal, QC, Canada., Lesokhin AM; Division of Hematology and Oncology, Memorial Sloan Kettering Cancer Center/Weill Cornell Medical College, New York, NY, USA.

المصدر: Nature medicine [Nat Med] 2023 Oct; Vol. 29 (10), pp. 2570-2576. Date of Electronic Publication: 2023 Oct 02.

نوع المنشور: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat Med Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/pathology , Anemia*/etiology, Humans ; B-Cell Maturation Antigen ; T-Lymphocytes/pathology ; Progression-Free Survival ; Immunotherapy, Adoptive/adverse effects

المؤلفون: Thompson MA; Aurora Cancer Care, Advocate Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI,. Electronic address: michael.thompson@tempus.com., Boccadoro M; Division of Hematology, University of Torino, Torino, Italy., Leleu X; Pôle Régional de Cancérologie, Department of Hematology, CHU La Milétrie-Poitiers, Poitiers, France., Vela-Ojeda J; Department of Hematology, UMAE Hospital de Especialidades Centro Medico La Raza IMSS, Mexico City, Mexico., van Rhee F; University of Arkansas for Medical Sciences, Little Rock, AR., Weisel KC; University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Rifkin RM; Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO., Usmani SZ; Levine Cancer Institute, Charlotte, NC., Hájek R; Department of Hemato-oncology, University Hospital Ostrava, and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Cook G; Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK., Abonour R; Indiana University School of Medicine, Indianapolis, IN., Armour M; Mijelom CRO, Croatian Myeloma Support Association, Zagreb, Croatia., Morgan KE; Myeloma Patients Europe, Brussels, Belgium., Yeh SP; China Medical University Hospital, Taichung City, P.R.China., Costello CL; University of California San Diego, La Jolla, CA., Berdeja JG; Department of Hematology, Tennessee Oncology and Sarah Cannon Research Institute, Nashville, TN., Davies FE; Perlmutter Cancer Center, NYU Langone, New York, NY., Zonder JA; Department of Malignant Hematology, Barbara Ann Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit, MI., Lee HC; Department of Lymphoma and Myeloma, The University of Texas M.D. Anderson Cancer Center, Houston, TX., Omel J; The Central Nebraska Myeloma Support Group, Grand Island, NE., Spencer A; Malignant Haematology and Stem Cell Transplantation Service, Alfred Health Monash University, Melbourne, Australia., Terpos E; Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece., Hungria VTM; Department of Hematology, Clinica São Germano and Santa Casa Medical School, São Paulo, Brazil., Puig N; Hematology Department, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC, Salamanca, Spain., Fu C; First Affiliated Hospital, Soochow University, Suzhou Jiangsu, P.R.China., Ferrari RH; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA., Ren K; Takeda Development Center Americas, Inc. (TDCA), Lexington, MA., Stull DM; Takeda Pharmaceuticals U.S.A., Inc., Lexington, MA., Chari A; Department of Hematology-Oncology, Mount Sinai School of Medicine, New York, NY.

المصدر: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2023 Mar; Vol. 23 (3), pp. e171-e181. Date of Electronic Publication: 2022 Dec 07.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma* , Influenza, Human*/prevention & control, Humans ; Prospective Studies ; Hospitalization ; Vaccination

المؤلفون: Costello CL; University of California San Diego, La Jolla, CA.

المصدر: Hematology. American Society of Hematology. Education Program [Hematology Am Soc Hematol Educ Program] 2022 Dec 09; Vol. 2022 (1), pp. 539-550.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 100890099 Publication Model: Print Cited Medium: Internet ISSN: 1520-4383 (Electronic) Linking ISSN: 15204383 NLM ISO Abbreviation: Hematology Am Soc Hematol Educ Program Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/therapy , Multiple Myeloma*/drug therapy , Hematopoietic Stem Cell Transplantation*/methods, Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bortezomib/therapeutic use

المؤلفون: Hájek R; University Hospital Ostrava & Faculty of Medicine, University of Ostrava, Ostrava, 703 00, Czech Republic., Minařík J; Palacky University & University Hospital Olomouc, Olomouc, 771 47, Czech Republic., Straub J; General Teaching Hospital, Prague, 128 08, Czech Republic., Pour L; University Hospital, Brno, 625 00, Czech Republic., Jungova A; Faculty Hospital Pilsen, Pilsen, 301 00, Czech Republic., Berdeja JG; Sarah Cannon Research Institute, Nashville, TN 37203, USA., Boccadoro M; University of Torino, Torino, 10124, Italy., Brozova L; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Spencer A; Alfred Health-Monash University, Melbourne, 3004, Australia., van Rhee F; University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA., Vela-Ojeda J; UMAE Especialidades Centro Medico La Raza IMSS, Ciudad de México, 02990, Mexico., Thompson MA; Advocate Aurora Research Institute, Advocate Aurora Health, Milwaukee, WI 53227, USA., Abonour R; Indiana University School of Medicine, Indianapolis, IN 46202, USA., Chari A; Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA., Cook G; Leeds Teaching Hospital, Leeds, LS1 3EX, UK., Costello CL; Moores Cancer Center, University of California San Diego, La Jolla, CA 92037, USA., Davies FE; Perlmutter Cancer Center, NYU Langone, New York, NY 10016, USA., Hungria VT; Clinica São Germano & Santa Casa Medical School, São Paulo, 04537-081, Brazil., Lee HC; M.D. Anderson Cancer Center, Houston, TX 77030, USA., Leleu X; Pôle Régional de Cancérologie, CHU de Poitiers, Poitiers, 86000, France., Puig N; Department of Hematology, Hospital Universitario de Salamanca (HUSAL), IBSAL, IBMCC (USAL-CSIC), CIBERONC (CB16/12/00233), Salamanca, 37007, Spain., Rifkin RM; Rocky Mountain Cancer Centers US Oncology Research, Denver, CO 80218, USA., Terpos E; National & Kapodistrian University of Athens, School of Medicine, Athens, 115 27, Greece., Usmani SZ; Levine Cancer Institute, Charlotte, NC 115 27, USA., Weisel KC; University Medical Center Hamburg-Eppendorf, Hamburg, 20251, Germany., Zonder JA; Barbara Ann Karmanos Cancer Institute / Wayne State University School of Medicine, Detroit, MI 48201, USA., Bařinová M; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Kuhn M; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Šilar J; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Čápková L; Institute of Biostatistics & Analyses, Ltd, Brno, 602 00, Czech Republic., Galvez K; Hospital Pablo Tobón Uribe, Medellin, 11001, Colombia., Lu J; Peking University People's Hospital, National Clinical Research Center for Hematologic Disease, Beijing, 100044, China., Elliott J; Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Stull DM; Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Ren K; Millennium Pharmaceuticals, Inc., Cambridge, MA 02139, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited., Maisnar V; Charles University Hospital & Faculty of Medicine, Hradec Králové, 121 08, Czech Republic.

المصدر: Future oncology (London, England) [Future Oncol] 2021 Jul; Vol. 17 (19), pp. 2499-2512. Date of Electronic Publication: 2021 Mar 26.

نوع المنشور: Journal Article; Multicenter Study; Observational Study

بيانات الدورية: Publisher: Future Medicine Ltd Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Multiple Myeloma/*drug therapy , Neoplasm Recurrence, Local/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Boron Compounds/administration & dosage ; Boron Compounds/adverse effects ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Drug Resistance, Neoplasm ; Female ; Glycine/administration & dosage ; Glycine/adverse effects ; Glycine/analogs & derivatives ; Humans ; Lenalidomide/administration & dosage ; Lenalidomide/adverse effects ; Male ; Middle Aged ; Multiple Myeloma/mortality ; Multiple Myeloma/pathology ; Neoplasm Recurrence, Local/mortality ; Progression-Free Survival ; Prospective Studies

المؤلفون: Terpos E; Plasma Cell Dyscrasias Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece. eterpos@hotmail.com., Mikhael J; Applied Cancer Research and Drug Discovery, Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA., Hajek R; Department of Hemato-Oncology, University Hospital Ostrava, and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic., Chari A; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Zweegman S; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, VU University Amsterdam, Amsterdam, The Netherlands., Lee HC; Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX, USA., Mateos MV; Department of Hematology, University Hospital of Salamanca, IBSAL, CIC, IBMCC (USAL-CSIC), Salamanca, Spain., Larocca A; Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy., Ramasamy K; Department of Haematology, Oxford University Hospitals NHS Foundation Trust, RDM, Oxford University, NIHR BRC Blood Theme, Oxford, UK., Kaiser M; Department of Haematology, The Royal Marsden Hospital, and Division of Molecular Pathology, The Institute of Cancer Research (ICR), London, UK., Cook G; Leeds Cancer Centre, Leeds Teaching Hospitals Trust, Leeds, UK., Weisel KC; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Costello CL; Department of Medicine, Division of Blood and Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, CA, USA., Elliott J; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Palumbo A; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA., Usmani SZ; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC, USA.

المصدر: Blood cancer journal [Blood Cancer J] 2021 Feb 18; Vol. 11 (2), pp. 40. Date of Electronic Publication: 2021 Feb 18.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Review

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma/*therapy, Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Clinical Trials, Phase III as Topic ; Disease Management ; Humans ; Quality of Life ; Treatment Outcome